Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
A.G. Johnson, T.V. Nguyen, R.O. Day.
Do nonsteroidal anti-inflammatory drugs affect blood pressure? A meta-analysis.
Ann Intern Med, 121 (1994), pp. 289-300
[2.]
E.R. Heerdink, H.G. Leufkens, R.M. Herings, J.P. Ottervanger, B.H. Stricker, A. Bakker.
NSAIDs associated with increased risk of congestive heart failure in elderly patients taking diuretics.
Arch InternMed, 158 (1998), pp. 1108-1112
[3.]
J. Page, D. Henry.
Consumption of NSAIDs and the development of congestive heart failure in elderly patients: an unrecognized public health problem.
Arch Intern Med, 160 (2000), pp. 777-784
[4.]
L.A. García Rodríguez, C. Varas, C. Patrono.
Differential effects of aspirin and non-aspirin nonsteroidal antiinflammatory drugs in the primary prevention of myocardial infarction in postmenopausal women.
Epidemiology, 11 (2000), pp. 382-387
[5.]
C. Bombardier, L. Laine, A. Reicin, D. Shapiro, R. Burgos-Vargas, B. Davis, VIGOR Study Group, et al.
Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group.
N Engl J Med, 343 (2000), pp. 1520-1528
[6.]
B.F. McAdam, F. Catella-Lawson, I.A. Mardini, S. Kapoor, J.A. Lawson, G.A. Fitzgerald.
Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2.
Proc Natl Acad Sci USA, 96 (1999), pp. 272-277
[7.]
F. Catella-Lawson, B. McAdam, B.W. Morrison, S. Kapoor, D. Kujubu, L. Antes, et al.
Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids.
J Pharmacol Exp Ther, 289 (1999), pp. 735-741
[8.]
R.S. Bresalier, R.S. Sandler, H. Quan, J.A. Bolognese, B. Oxenius, K. Horgan, et al.
Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial.
N Engl J Med, 352 (2005), pp. 1092-1102
[9.]
S.A. Reines, G.A. Block, J.C. Morris, G. Liu, M.L. Nessly, C.R. Lines, et al.
Rofecoxib: No effect on Alzheimer's disease in a 1-year, randomized, blinded, controlled study.
Neurology, 62 (2004), pp. 66-71
[10.]
S.D. Solomon, J.J. McMurray, M.A. Pfeffer, J. Wittes, R. Fowler, P. Finn, Adenoma Prevention with Celecoxib (APC) Study Investigators, et al.
Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention.
N Engl J Med, 352 (2005), pp. 1071-1080
[11.]
F.E. Silverstein, G. Faich, J.L. Goldstein, L.S. Simon, T. Pincus, A. Whelton, et al.
Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial: Celecoxib Long-term Arthritis Safety Study.
JAMA, 284 (2000), pp. 1247-1255
[12.]
W.B. White, G. Faich, A. Whelton, C. Maurath, N.J. Ridge, K.M. Verburg, et al.
Comparison of thromboembolic events in patients treated with celecoxib, a cyclooxygenase-2 specific inhibitor, versus ibuprofen or diclofenac.
Am J Cardiol, 89 (2002), pp. 425-430
[13.]
G. Singh, J.G. Fort, J.L. Goldstein, R.A. Levy, P.S. Hanrahan, A.E. Bello, et al.
for the SUCCESS-I Investigators Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-I Study.
Am J Med, 119 (2006), pp. 255-266
[14.]
N. Arber, C.J. Eagle, J. Spicak, I. Racz, P. Dite, J. Hajer, et al.
PreSAP Trial Investigators. Celecoxib for the prevention of colorectal adenomatous polyps.
N Engl J Med, 355 (2006), pp. 885-895
[15.]
P. McGettigan, D. Henry.
Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2.
JAMA, 296 (2006), pp. 1633-1644
[16.]
G.A. FitzGerald, C. Patrono.
The COXIBs, selective inhibitors of cyclooxygenase-2.
N Engl J Med, 345 (2001), pp. 433-442
[17.]
L.A. García Rodríguez, P. Patrignani.
The ever growing story of cyclooxygenase inhibition.
Lancet, 368 (2006), pp. 1745-1747
[18.]
C.P. Cannon, S.P. Curtis, G.A. FitzGerald, H. Krum, A. Kaur, J.A. Bolognese, for the MEDAL Steering Committee, et al.
Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison.
Lancet, 368 (2006), pp. 1771-1781
[19.]
F. Andersohn, S. Suissa, E. Garbe.
Use of first- and second-generation cyclooxygenase-2-selective nonsteroidal antiinflammatory drugs and risk of acute myocardial infarction.
Circulation, 113 (2006), pp. 1950-1957
[20.]
A. Helin-Salmivaara, A. Virtanen, R. Vesalainen, J.M. Gronroos, T. Klaukka, J.E. Idanpaan-Heikkila, et al.
NSAID use and the risk of hospitalization for first myocardial infarction in the general population: a nationwide case-control study from Finland.
Eur Heart J, 14 (2006), pp. 1657-1663
[21.]
European Medicines Agency statement on the suspension of use of Bextra [nota de prensa]. European Medicines Agency; 7 abril 2005 [citado Nov 2006]. Disponible en: http://www.emea.eu.int/pdfs/human/press/pus/ 12163705en.pdf
[22.]
EMEA public statement on valdecoxib (Bextra/Valdyn) and parecoxib Sodium (Dynastat/Rayzon) Cardiovascular risks in coronary artery bypass graft (cabg) Surgery and serious adverse skin reactions [nota de prensa]. European Medicines Agency; 15 diciembre 2004 [citado Nov 2006]. Disponible en: http://www.emea.eu.int/pdfs/human/press/pus/20480204en.pdf
[23.]
N.A. Nussmeier, A.A. Whelton, M.T. Brown, R.M. Langford, A. Hoeft, J.L. Parlow, et al.
Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery.
N Engl J Med, 352 (2005), pp. 1081-1091
[24.]
ADAPT Research Group.
Cardiovascular and cerebrovascular events in the randomized, controlled Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT).
PLoS Clin Trials, 1 (2006), pp. e33
[25.]
S. Hernández-Díaz, C. Varas-Lorenzo, L.A. García Rodríguez.
Nonsteroidal antiinflammatory drugs and the risk of acute myocardial infarction.
Basic Clin Pharmacol Toxicol, 98 (2006), pp. 266-274
[26.]
F. Catella-Lawson, M.P. Reilly, S.C. Kapoor, A.J. Cucchiara, S. DeMarco, B. Tournier, et al.
Cyclooxygenase inhibitors and the antiplatelet effects of aspirin.
N Engl J Med, 345 (2001), pp. 1809-1817
[27.]
T.M. MacDonald, L. Wei.
Effect of ibuprofen on cardioprotective effect of aspirin.
Lancet, 361 (2003), pp. 573-574
[28.]
T.N. Patel, K.C. Goldberg.
Use of aspirin and ibuprofen compared with aspirin alone and the risk of myocardial infarction.
Arch Intern Med, 164 (2004), pp. 852-856
[29.]
European Medicines Agency. CHMP review on non-selective nonsteroidal anti-inflammatory drugs (NSAIDs) [citado Nov 2006]. Disponible en: http://www.emea.eu.int/htms/human/opiniongen/nsaids06.htm
[30.]
Agencia Española del Medicamento y Productos Sanitarios. Nota informativa de la Agencia Española del Medicamento sobre riesgos de tipo aterotrombótico de los Coxib y AINE tradicionales. 26 de octubre de 2006 [citado Nov 2006]. Disponible en: http://www.agemed.es/actividad/alertas/usoHumano/seguridad/coxibsoct06. htm
Copyright © 2007. Elsevier España S.L. Barcelona
